Business Daily Media

Men's Weekly

.

CK Life Sciences’ Investigational Cancer Vaccines Deliver Promising Results - New Preclinical Study Data to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

HONG KONG SAR - Media OutReach Newswire - 22 April 2025 - CK Life Sciences Int'l., (Holdings) Inc. ("the Company") announced that the Company will be presenting new data from its cancer vaccine research pipeline at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, USA.



The AACR Annual Meeting is a gathering central to the global cancer research community, bringing together scientists, clinicians, other healthcare professionals, survivors, patients and advocates every year to share the latest breakthroughs and developments in cancer science and medicine. Last year, the 2024 Annual Meeting attracted 23,000 in-person attendees and 6,700 online participants from 78 countries.

In recent years, CK Life Sciences has regularly participated at the AACR Annual Meeting. The 2025 Annual Meeting will be held from 25-30 April. At the event, CK Life Sciences will exhibit posters highlighting data from preclinical studies of investigational cancer vaccines programs targeting (i) PRAME (Preferentially Expressed Antigen in Melanoma), (ii) PD-L1 (programmed cell death ligand 1), (iii) B7-H3 (B7 homolog 3) and (iv) Claudin 6 proteins, respectively.

PRAME is a protein highly expressed in several cancers, including melanoma, liver cancer and leukemia.

PD-L1 is one of the most important immune checkpoint proteins that is highly expressed in cancer cells to block T cell activation in the tumour microenvironment.

B7-H3 is another immune checkpoint protein that modulates T cell responses and is often overexpressed in cancer.

Claudin 6 is a tight junction protein that regulates epithelial barrier integrity and is overexpressed in cancers like breast cancer, lung cancer and endometrial cancer, where it is associated with tumour progression and metastasis.

In addition, CK Life Sciences will be co-presenting with our research collaborator two posters showcasing our Artificial Intelligence (AI)-empowered platform for designing cancer vaccines.

"CK Life Sciences is pleased with the preclinical efficacy results of its investigational cancer vaccines targeting PRAME, PD-L1, B7-H3 and Claudin 6 proteins, and we hope to further advance the research & development of these and other cancer vaccines. We are also excited about the progress achieved in our efforts to develop an AI platform aimed at designing cancer vaccines that are more likely to be immunogenic and clinically effective," said Melvin Toh, Vice President and Chief Scientific Officer at CK Life Sciences.

Dr. Toh continued, "CK Life Sciences is determined to accelerate its R&D to benefit cancer patients. Currently, a number of therapeutic cancer vaccines are in clinical and discovery/preclinical research stages. Amongst them, seviprotimut-L, a cancer vaccine already in the final research stage, is being tested for the adjuvant treatment of stage IIB or IIC melanoma following definitive surgical resection.

DETAILS ON POSTER PRESENTATIONS:

  • Abstract 853: PDL1-PRAME dual antigen cancer vaccine inhibits melanoma growth in syngeneic mouse model and induces antigen-specific immune responses
Authors: Kin-Tak Chan, Hsin-Wei Chen, Pi-Hui Liang, You-Yu Lin, Tristan Zhang, Melvin Toh

Session Category: Clinical Research
Session Title: Vaccines and Cell Therapies
Session Date and Time: 4/27/2025 2:00 PM - 5:00 PM
Location: Poster Section 35
Poster Board Number: 9

  • Abstract 3533: Claudin 6 vaccines effectively inhibit tumor growth in a syngeneic mouse colon cancer model
Authors: Na Wang, Melvin Toh, Hong Wang

Session Category: Immunology
Session Title: Vaccines, In Situ Vaccines, and Vaccine Combinations
Session Date and Time: 4/28/2025 2:00 PM - 5:00 PM
Location: Poster Section 39
Poster Board Number: 9

  • Abstract 3536: Synergistic effects of combined PD-L1 and B7-H3 fusion protein vaccination in a mouse model of pancreatic cancer
Authors: Kenneth Nansheng Lin, Melvin Toh, Hong Wang

Session Category: Immunology
Session Title: Vaccines, In Situ Vaccines, and Vaccine Combinations
Session Date and Time: 4/28/2025 2:00 PM - 5:00 PM
Location: Poster Section 39
Poster Board Number: 12

  • Abstract 3538: The development of neoantigen-derived peptide vaccine driven by AI epitope design and computer assisted epitope enhancement
Authors: Chi Han Samson Li, Hong Wang, Kin Tak Chan, Genwei Zhang, Jiewen Du, Lipeng Lai, Melvin Toh

Session Category: Immunology
Session Title: Vaccines, In Situ Vaccines, and Vaccine Combinations
Session Date and Time: 4/28/2025 2:00 PM - 5:00 PM
Location: Poster Section 39
Poster Board Number: 14

  • Abstract 3649: Artificial intelligence accelerates shared neoantigen peptide cancer vaccine development
Authors: Genwei Zhang, Jiewen Du, Xiangrui Gao, Zhenghui Wang, Qingxia Zhang, Tongren Liu, Dong Chen, Chi Han Samson Li, Kin Tak Chan, Hong Wang, Melvin Toh, Lipeng Lai

Session Category: Bioinformatics/ Computational Biology/ Systems Biology/ Convergent Science
Session Title: Artificial Intelligence and Machine Learning for Therapeutic Election and Discovery
Session Date and Time: 4/28/2025 2:00 PM - 5:00 PM
Location: Poster Section 45
Poster Board Number: 11

The full abstracts are available in the AACR Online Itinerary Planner, which can be accessed at: https://www.abstractsonline.com/pp8/#!/20273

DISCLAIMER
This press release may contain forward-looking statements regarding the Group’s research and development projects which may involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements.
All information in this press release is for general reference only and is not intended as investment advice or medical advice. CK Life Sciences Int'l., (Holdings) Inc. does not warrant or represent, express or implied, as to the accuracy, completeness or updated status of such information. No liability will be accepted for any loss or damage howsoever arising from or in reliance upon such information.

Copyright ©2025 CK Life Sciences Int’l., (Holdings) Inc. All rights reserved.

Hashtag: #CKLifeSciences #CancerVaccines #R&D #Pharmaceutical #AmericanAssociationforCancerResearch #AACR #PRAME #PD-L1 #B7-H3 #Claudin6Proteins #Melanoma #AI

The issuer is solely responsible for the content of this announcement.

News from Asia

inDrive Launched 0% Commission Program to Protect Driver’s Income During Emergency Situation

JAKARTA, INDONESIA - Media OutReach Newswire - 10 September 2025 - inDrive, a global urban mobility platform, reaffirms its commitment to prioritizing the welfare of drivers. As a support measure ...

REMA TIP TOP Acquires Key Assets of Almex Group, Strengthening Global Position in Conveyor Technology

MUNICH, GERMANY - Newsaktuell - 10 September 2025 - REMA TIP TOP acquires significant assets and operations of the Canadian Almex Group. With the acquisition, the company expands its portfolio in t...

Vantage Data Centers Secures $1.6B Investment in APAC Platform from GIC and ADIA

Investment to support accelerated expansion in APAC, including acquisition of hyperscale data center campus in Johor, Malaysia, strengthening Vantage’s position as a market leader in Asia Pacific D...

AUX Commences Trading on Hong Kong Stock Exchange, Launching New Chapter in Global Growth

HONG KONG SAR - Media OutReach Newswire - 10 September 2025 - AUX Electric Co., Ltd. (Stock Code: 2580.HK), the core air conditioning business of AUX Group, listed on the Hong Kong Stock Exchange ...

BeOne Medicines Honored with the Global Oncology Innovation Leadership Award at BIOHK 2025, Supporting "1+" to Accelerate the Delivery of Innovative Cancer Therapies

HONG KONG SAR - Media OutReach Newswire - 11 September 2025 - BeOne Medicines (BeOne)(NASDAQ: ONC; HKEX: 06160; SSE: 688235), was honored today at BIOHK 2025, the Hong Kong International Biotechno...

Gree Showcases Photovoltaic DC Air Conditioning System at Gree Summit Partner, Positioning Singapore as Green Innovation Hub

SINGAPORE - Media OutReach Newswire - 11 September 2025 - Singapore has long been recognized as a pivotal hub in Gree's Southeast Asia growth strategy. With its advanced infrastructure, strong sus...

TIYA Conference 2025: Over 150 Youth Leaders from 15 Countries Gathered to Advance United Nations’ SDGs

Three-day conference in Singapore empowers young changemakers through mentorship and international collaborationSINGAPORE - Media OutReach Newswire - 11 September 2025 - Tzu-Chi Foundation (Singap...

Finex Collaborates with Sharing Happiness to Honor Indonesian Veterans

JAKARTA, INDONESIA - Media OutReach Newswire - 11 September 2025 - Finex, an acclaimed Indonesian broker, and Sharing Happiness, a charity organization, partnered to honor the members of the Indo...

Momcozy Honored at Kind+Jugend 2025 for Innovation in Maternal Care

COLOGNE, GERMANY - Media OutReach Newswire - 11 September 2025 - Momcozy, a global leader in maternal care and a pioneer of the Mom-First philosophy, announced at Kind+Jugend that its Ergonest M...

Australian representation at CIFTIS reflects deepening cooperation with China: experts

BEIJING, CHINA - Media OutReach Newswire - 11 September 2025 - The 2025 China International Fair for Trade in Services (CIFTIS) reflects the deepening cooperation between China and Australia in se...

AWS research shows strong AI adoption momentum in Australia, with startups outpacing large enterprises in innovation

Amazon Web Services (AWS), an Amazon.com company, released new research revealing that while artificial intelligence (AI) adoption continues to acce...

Changing the World One Bite At a Time: IKU Turns 40

One of Australia’s first plant-based, chef-led eateries and now ready meal provider IKU is celebrating its 40 year anniversary with the business e...

Three generations marking 45 years in hot-air balloons

Australia’s leading hot-air balloon company is celebrating 45 years in the sky and its 700,000th passenger, driven by the passion of father-son du...

Workplace DMs, Reinvented: Deputy Messaging, Purpose-Built For Shift-Based Teams

Deputy, the global people platform for shift-based businesses, has launched Deputy Messaging, a fully integrated, real-time communication tool designe...

Revolutionizing Fulfillment: How Virtual Warehousing is Changing the Game?

The e-commerce landscape is evolving more rapidly than ever, and the way businesses are managing their fulfillment is also revolutionizing. At the...

SME lender Dynamoney welcomes new CEO, Brett Thomas

Strengthens growth ambitions and signals expanded offering Dynamoney, a leading commercial finance provider for Australian SMEs,  has today appoint...

Sell by LayBy